metaEvidence - overview


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	nivolumab plus cabozantinib vs. sunitinib	1	none	inconclusive results for: DOR; DOR (extension); TRAE (any grade); TRAE leading to death (grade 5); TRAE leading to discontinuation (any grade)	statistically conclusive 40 % decrease in deaths (OS) but the degree if certainty is unassessable suggested 30 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable suggested 44 % decrease in PFS (extension) but the degree if certainty is unassessable statistically conclusive 49 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable statistically conclusive 3.4-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 3.2-fold increase in objective responses (ORR) (extension) but the degree if certainty is unassessable	-
mRCC - L1 - PDL1 negative metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 negative
mRCC - L1 - PDL1 positive metastatic/advanced RCC (mRCC) - 1st line (L1) mRCC - L1 - PDL1 positive
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)